CClinicalTrials.gg
Not yet recruitingNCT07521904Updated Apr 13, 2026

Naturopathic Approaches to Ulcerative Colitis

An observational study in Ulcerative Colitis, sponsored by National University of Natural Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by National University of Natural Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Ulcerative colitis (UC) is a long-term condition that causes inflammation in the large intestine. People with UC often have symptoms such as diarrhea, abdominal pain, and fatigue. These symptoms can come and go over time and can have a major impact on daily life. Although there are many medical treatments available, some patients do not respond well, experience side effects, or prefer to avoid long-term use of medications that affect the immune system. Because of this, many people with UC seek care from naturopathic doctors.

This study aims to better understand how naturopathic care is used to treat UC and whether patients experience changes in their symptoms over time. In this study, adults with UC who are already receiving care from a naturopathic doctor will be followed for 12 weeks. The treatments will not be standardized; instead, each naturopathic doctor will provide individualized care based on their usual practice.

Participants will complete a questionnaire that measures UC symptoms at the start of the study and again after 12 weeks. The study will compare symptom scores before and after treatment. Researchers will also collect information about the types of treatments used and any side effects or adverse events.

This is an observational study, meaning there is no comparison group and no changes are made to participants' usual care. The goal is to gather early information about naturopathic care for UC and to help guide future, more rigorous studies.

Read the detailed description

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by relapsing and remitting inflammation of the colonic mucosa. UC carries a significant burden in terms of quality of life, healthcare utilization, and long-term risk of colorectal cancer. While numerous pharmaceutical therapies exist-including aminosalicylates, corticosteroids, immunomodulators, biologics, and small molecules-many patients experience suboptimal response, adverse effects, or prefer to avoid long-term immunosuppression. As a result, many individuals with UC seek out complementary and alternative medicine, including naturopathic care. However, naturopathic approaches to UC are understudied. The investigators aim to describe naturopathic approaches to UC and to establish pilot data on before-and-after changes in validated UC instruments. The study will employ a prospective, observational, naturalistic design. The uncontrolled before-and-after study will examine the outcomes associated with individualized, whole system naturopathic care as determined by each respective provider. The investigators will recruit adult patients diagnosed with ulcerative colitis who are under the care of naturopathic doctors. Participants' UC symptoms will be measured using a validated instrument, the Patient-Modified Simple Clinical Colitis Activity Index [P-SCCAI]. Adverse events and treatment descriptions will also be collected. The primary outcomes will be before-and-after differences using week 12 as the primary endpoint. P-values will be set at 0.05 and descriptive and summary data will be presented. This study is designed to address substantial evidence gaps and to gather preliminary evidence to inform the design of a future randomized, controlled trial.

02

Conditions studied

  • Ulcerative Colitis

Keywords

  • naturopathy
  • naturopathic medicine
  • UC
  • ulcerative colitis
  • IBD
  • inflammatory bowel disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible participants are adults (≥18 years of age) who present to the clinical co-investigators' practices with UC as the primary cause of their visit.

Inclusion criteria

*Adults (≥18 years of age) who have active UC (P-SCCAI >4)

Exclusion criteria

Exclusion Criteria:

*Inability to read and write in English.

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • OtherNaturopathic medicine

    Whole system naturopathic medicine

05

What researchers measure

Primary outcomes

  1. Patient-Modified Simple Clinical Colitis Activity Index

    There are over 30 patient reported outcomes (PRO) instruments in use for patients with IBD.14 The oldest and most widely used is the Patient-Modified Simple Clinical Colitis Activity Index \[P-SCCAI\], a validated, non-proprietary patient-reported outcome measure for ulcerative colitis. The P-SCCAI is a patient-worded version of the Simple Clinical Colitis Activity Index and includes six symptom domains: stool frequency (day and night), urgency, rectal bleeding, general well-being, and extra-intestinal manifestations. Total scores range from 0-19, with ≥5 commonly used to define active disease.

    Time frame: 6 months

  2. Health Status

    PROMIS-29 The Patient Reported Outcomes Measurement Information System (PROMIS) provides a standardized, reliable, and valid measure of health status. The profile is a collection of self-report short forms containing items from seven PROMIS domains (Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Pain Interference, and Pain Intensity). The PROMIS-29 Profile consists of four questions per domain rated on a 5-point rating scale along with a 1 question Pain Intensity section rated on an 11-point scale. A raw score ranges from 29 to 150, and can be converted into T-scores which are referenced to mean score levels in the general U.S. population. Lower PROMIS scores have been shown to predict reduced health related quality of life for multiple chronic conditions. We will measure average change in each participant's PROMIS - 29 score from week zero to week twelve and twenty four.

    Time frame: 6 months

Secondary outcomes

  1. CARE

    The clinician's interpersonal practice will be assessed using the Consultation and Relational Empathy (CARE) Measure, a validated 10-item patient-reported instrument that evaluates practitioner empathy during the clinical encounter. Each item is scored from 1 to 5, yielding a total score range of 10 to 50, with higher scores indicating greater perceived clinician empathy. The CARE Measure has demonstrated validity and reliability in multiple health care settings and has also been used to assess interpersonal aspects of care in integrative medicine contexts. Outcome assessment will occur over 6 months.

    Time frame: 6 months

  2. Patient empowerment

    The 5-item Empowerment scale will be employed to evaluate the patient experiences of the clinical consultation with regards to the degree to which the practitioner encourages patient empowerment. Each item is scored on a Likert scale from 1 to 5, yielding a total score range of 5 to 25, with higher scores indicating greater patient empowerment. Outcome assessment will occur over 6 months.

    Time frame: 6 months

  3. The Patient-Centered Care-Perceived Provider Support-Empowerment Scale

    The Patient-Centered Care-Perceived Provider Support-Empowerment Scale is a trifecta of validated instruments developed to assess patients' perceptions of provider support, patient-centered care, and empowerment as they relate to health outcomes. These questionnaires aim at measuring the impact of the therapeutic relationship, the philosophy of healing, and CIH-specific techniques on treatment effects. Each component instrument will be scored according to its validated scoring system, with item responses rated on Likert scales (e.g., 1 to 4 or 1 to 5). For all included measures, higher scores indicate greater perceived patient-centeredness, provider support, and patient empowerment. Outcome assessment will occur over 6 months.

    Time frame: 6 months

  4. Treatment characteristics

    Prescribed treatments (e.g. diets, supplements, medications, lifestyle changes), including doses and frequencies with be extracted from chart notes.

    Time frame: 6 months

  5. Adverse Events

    Total number of adverse events and serious adverse events (using NIH's Common Terminology Criteria for Adverse Events version 4.0). This will be measured by practitioner report using chart abstraction. Practitioners will be trained on grading and documenting adverse events, as well as using standardized AE forms, before subjects are enrolled.

    Time frame: 6 months

06

Study locations

1 site
  • Helfgott Research Institute - National University of Natural Medicine
    Portland, Oregon 97201, United States
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07521904
Lead sponsor
National University of Natural Medicine
Collaborators
Gastroenterology Association of Naturopathic Physicians
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Joshua Goldenberg, ND
Contact
jgoldenberg@nunm.edu
2068830119
Mark Davis, ND
Contact
markdavisnd@gmail.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion